Cyclerion Therapeutics

Cyclera Therapeutics

This company develops catalytic protein degradation therapeutics to treat neuropsychiatric, neurodegenerative and cancer disorders for patients with central nervous system diseases.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Autobahn Therapeutics

This company develops brain-penetrating small molecule therapies for patients with neuropsychiatric and neuroimmunologic disorders, including depression and multiple sclerosis.